This HTML5 document contains 83 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n6http://linked.opendata.cz/resource/mesh/concept/
rdfshttp://www.w3.org/2000/01/rdf-schema#
n7http://linked.opendata.cz/resource/fda-spl/ingredient/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/mesh/
owlhttp://www.w3.org/2002/07/owl#
ncihttp://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#
xsdhhttp://www.w3.org/2001/XMLSchema#

Statements

Subject Item
nci:C1687
rdf:type
owl:Class
rdfs:label
Imatinib Mesylate
owl:equivalentClass
_:vb633887
nci:A6
nci:C62035
nci:A7
nci:C17322 nci:C17328 nci:C16325
nci:A8
nci:C63923
nci:P106
Pharmacologic Substance Organic Chemical
nci:P108
Imatinib Mesylate
nci:P175
716051
nci:P207
C0939537
nci:P210
220127-57-1
nci:P302
Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia, gastrointestinal stromal tumor, hypereosinophillic syndrome, dermatofibrosarcoma protuberans, mutated-PDGFR myelodysplastic/myeloproliferative diseases.
nci:P303
Metastatic dermatofibrosarcoma protuberans; myelofibrosis; ovarian epithelial; fallopian tube; or primary peritoneal cancer; prostate cancer; small cell lung cancer; unspecified solid tumors; uterine carcinoma Acute lymphoblastic leukemia; breast cancer; chronic myelogenous leukemia; colorectal cancer; gastrointestinal neoplasms; glioma; melanoma; Merkel cell carcinoma
nci:P319
8A1O1M485B
nci:P322
FDA
nci:P325
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>A drug used to treat different types of leukemia and other cancers of the blood, gastrointestinal stromal tumors, skin tumors called dermatofibrosarcoma protuberans, and a rare condition called systemic mastocytosis. It is also being studied in the treatment of other types of cancer. Imatinib mesylate blocks the protein made by the bcr/abl oncogene. It is a type of tyrosine kinase inhibitor.</n0:def-definition><n0:def-source>NCI-GLOSS</n0:def-source></n0:ComplexDefinition>
nci:P329
37862
nci:P330
37862
nci:P350
C29H31N7O.CH4O3S
nci:P366
Imatinib
nci:P368
CHEBI:31690
nci:P90
<n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>imatinib mesylate</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000044893</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Gleevec</n0:term-name><n0:term-group>BR</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Gleevec</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0716051</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CGP 57148</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Gleevec</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000258252</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>CGP57148B</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Glivec</n0:term-name><n0:term-group>FB</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Imatinib Mesylate</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>STI 571</n0:term-name><n0:term-group>SY</n0:term-group><n0:term-source>DTP</n0:term-source><n0:source-code>NSC0716051</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>STI571</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>NCI-GLOSS</n0:term-source><n0:source-code>CDR0000043975</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>Imatinib Mesylate</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>DCP</n0:term-source><n0:source-code>50363</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>STI-571</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>IMATINIB MESYLATE</n0:term-name><n0:term-group>PT</n0:term-group><n0:term-source>FDA</n0:term-source><n0:source-code>8A1O1M485B</n0:source-code></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>STI571</n0:term-name><n0:term-group>CN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm> <n0:ComplexTerm xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:term-name>4-[(4-Methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide Monomethanesulfonate</n0:term-name><n0:term-group>SN</n0:term-group><n0:term-source>NCI</n0:term-source></n0:ComplexTerm>
nci:P97
<n0:ComplexDefinition xmlns:n0="http://ncicb.nci.nih.gov/xml/owl/EVS/ComplexProperties.xsd#"><n0:def-definition>The mesylate salt of imatinib, a tyrosine kinase inhibitor with antineoplastic activity. Imatinib binds to an intracellular pocket located within tyrosine kinases (TK), thereby inhibiting ATP binding and preventing phosphorylation and the subsequent activation of growth receptors and their downstream signal transduction pathways. This agent inhibits TK encoded by the bcr-abl oncogene as well as receptor TKs encoded by the c-kit and platelet-derived growth factor receptor (PDGFR) oncogenes. Inhibition of the bcr-abl TK results in decreased proliferation and enhanced apoptosis in malignant cells of Philadelphia-positive (Ph+) hematological malignancies such as CML and ALL; effects on c-kit TK activity inhibit mast-cell and cellular proliferation in those diseases overexpressing c-kit, such as mastocytosis and gastrointestinal stromal tumor (GIST).</n0:def-definition><n0:def-source>NCI</n0:def-source></n0:ComplexDefinition>
nci:code
C1687
owl:sameAs
n7:8A1O1M485B
n5:hasConcept
n6:M0391958
Subject Item
_:vb633887
rdf:type
owl:Class
owl:intersectionOf
_:vb737436
Subject Item
_:vb682238
rdf:type
owl:Restriction
owl:onProperty
nci:R150
owl:someValuesFrom
nci:C37042
Subject Item
_:vb682239
rdf:type
owl:Restriction
owl:onProperty
nci:R146
owl:someValuesFrom
nci:C17660
Subject Item
_:vb682240
rdf:type
owl:Restriction
owl:onProperty
nci:R124
owl:someValuesFrom
nci:C40704
Subject Item
_:vb682241
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C20150
Subject Item
_:vb682242
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C20751
Subject Item
_:vb682243
rdf:type
owl:Restriction
owl:onProperty
nci:R125
owl:someValuesFrom
nci:C40821
Subject Item
_:vb682244
rdf:type
owl:Restriction
owl:onProperty
nci:R122
owl:someValuesFrom
nci:C17573
Subject Item
_:vb737436
rdf:first
nci:C1967
rdf:rest
_:vb767384
Subject Item
_:vb767384
rdf:first
_:vb682238
rdf:rest
_:vb767385
Subject Item
_:vb767385
rdf:first
_:vb682239
rdf:rest
_:vb767386
Subject Item
_:vb767386
rdf:first
_:vb682240
rdf:rest
_:vb767387
Subject Item
_:vb767387
rdf:first
_:vb682241
rdf:rest
_:vb767388
Subject Item
_:vb767388
rdf:first
_:vb682242
rdf:rest
_:vb767389
Subject Item
_:vb767389
rdf:first
_:vb682243
rdf:rest
_:vb767390
Subject Item
_:vb767390
rdf:first
_:vb682244
rdf:rest
rdf:nil